News | Embolic Protection Devices | May 08, 2018

Sentinel Cerebral Protection System Reduces TAVR Strokes More Than 60 Percent

Device captures debris in 99 percent of patients undergoing TAVR

Sentinel Cerebral Protection System Reduces TAVR Strokes More Than 60 Percent

May 8, 2018 — One-year results from the Sentinel Cerebral Protection System show it can reduce the incidence of stroke during transcatheter aortic valve replacement (TAVR) by more than 60 percent. Since its clearance by the U.S. Food and Drug Administration (FDA) a year ago, the technology is now used by more than 10 percent of TAVR centers nationwide, according to manufacturer Claret Medical.

The Sentinel Cerebral Protection System protects patients by filtering, capturing and removing pieces of tissue, calcium and other harmful debris released during TAVR before it can reach the brain. Such debris could cause a blockage, potentially leading to a stroke. Studies have shown that the Sentinel technology captures debris in 99 percent of patients undergoing TAVR and has no safety risks associated with it.

Sentinel patient Jim McCutchon of Corpus Christi, Texas said, “Having aortic stenosis is like flirting with sudden death. My aortic valve was closing down slowly, and I had to stop to catch my breath even with no greater exercise than a leisurely walk. I needed TAVR, but I was concerned that I would have a stroke if I had TAVR without cerebral protection. I struggled with a three-year wait until Sentinel was available, and then I felt confident to move forward with the procedure. I’ve seen pictures of the debris that Sentinel captured on the way to my brain, and I am thankful that I waited. Since then, I have had no problems, and I can run and play again.”

“We would never drive a car without a seatbelt and we should never do TAVR without embolic protection,” said Susheel Kodali, M.D., from New York-Presbyterian Hospital.

“Stroke destroys lives, and it is important that we as physicians do all we can to prevent it. With this in mind, we now use Sentinel technology in all our TAVR cases and have been able to provide greater brain protection to patients,” said Samir Kapadia, M.D., with the Cleveland Clinic.

For more information: www.claretmedical.com

 

Related Content

Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
Videos | Cath Lab | September 14, 2018
A discussion with Nicolas Bevins, Ph.D., vice chair, physics and research, and Jessica Harrington, RCIS.
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Overlay Init